This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -50% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, OrthoPediatrics (KIDS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OrthoPediatrics (KIDS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -31.82% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates
by Zacks Equity Research
RxSight (RXST) delivered earnings and revenue surprises of -70% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 10.53% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -50% and 1.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes OrthoPediatrics (KIDS) a New Strong Buy Stock
by Zacks Equity Research
OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
by Zacks Equity Research
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.
Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
by Zacks Equity Research
BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.
New Animal Health Products, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.
Down -15.65% in 4 Weeks, Here's Why You Should You Buy the Dip in OrthoPediatrics (KIDS)
by Zacks Equity Research
OrthoPediatrics (KIDS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?
by Zacks Equity Research
Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
by Zacks Equity Research
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan
by Zacks Equity Research
Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.
HOLX Stock Gains From New Offerings Despite Macro Issues
by Zacks Equity Research
In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.
VRNOF Stock Likely to Gain From Its Newly Opened Dispensary in Phoenix
by Zacks Equity Research
Verano is set to open a new Zen Leaf Arcadia in Phoenix, AZ, today. Zen Leaf Arcadia is located at 2710 E Indian School Road, Phoenix. It will be open daily from 8 a.m. to 10 p.m. local time.
Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock
by Zacks Equity Research
Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
by Zacks Equity Research
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
Bears are Losing Control Over OrthoPediatrics (KIDS), Here's Why It's a 'Buy' Now
by Zacks Equity Research
OrthoPediatrics (KIDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
by Zacks Equity Research
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.